Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 8/20 | 0.53 |
| ▸ | KLK1 | P06870 | 7/20 | 0.53 |
| ▸ | KLK6 | Q92876 | 6/20 | 0.53 |
| ▸ | KLKB1 | P03952 | 5/20 | 0.51 |
| ▸ | PLAU | P00749 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.48 |
| ▸ | PLAT | P00750 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7444704 | 0.98 | PLG (0.54) | PLGKLK1KLK6KLKB1PLAU | |
| SCHEMBL27905664 | 0.84 | RAB9A (0.58) | PLGKLK1KLK6KLKB1PLAU | |
| SCHEMBL19668154 | 0.83 | HTR6 (0.49) | CYP1A2CYP2C19LOXL2 | |
| SCHEMBL4317924 | 0.83 | PTPN11 (0.55) | PLGKLK1KLK6KLKB1PLAU | |
| SCHEMBL27644382 | 0.83 | KLKB1 (0.51) | PLGKLK1KLK6KLKB1PLAU | |
| SCHEMBL8530522 | 0.83 | PEPD (0.59) | PLGKLK1KLK6KLKB1PLAU | |
| SCHEMBL29092627 | 0.82 | POLB (0.50) | HDAC3HDAC6 | |
| SCHEMBL2762349 | 0.82 | POLB (0.62) | TSHR | |
| SCHEMBL545945 | 0.82 | SMN1; SMN2 (0.65) | TSHR | |
| SCHEMBL7307424 | 0.81 | SMN1; SMN2 (0.47) | PLGKLK1KLK6KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106046100-A | 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, methods for the production thereof and the use thereof for treating diseases | 拜耳知识产权有限责任公司 | 2016-10-26 | — | — | CN | claimed |
| CN-102596985-A | 17-hydroxy-17-pentafluoroethyl-estra-4, 9(10) -dien-11-aryl derivatives, method for the production thereof and use thereof for treating diseases | BAYER SCHERING PHARMA AG | 2012-07-18 | — | — | CN | claimed |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240189440-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-06-13 | — | — | US | disclosed |
| US-11987568-B2 | Allosteric inhibitor of WEE1 kinase | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| EP-3778573-B1 | COMPOUND WITH ANTICANCER ACTIVITY | KYOWA KIRIN CO LTD (JP) | 2024-04-24 | — | — | EP | disclosed |
| WO-2024076929-A2 | IRREVERSIBLE INACTIVATORS TARGETING ARAF/MEK COMPLEXES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| EP-4301417-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | The Research Foundation for The State University of New York (US) | 2024-01-10 | — | — | EP | disclosed |
| WO-2023196473-A2 | SMALL MOLECULE INHIBITORS OF ID PROTEINS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230159554-A1 | COMPOUND WITH ANTICANCER ACTIVITY | KYOWA KIRIN CO., LTD. (JP) | 2023-05-25 | — | — | US | disclosed |
| US-11629152-B2 | Compound with anticancer activity | KYOWA KIRIN CO., LTD. (JP) | 2023-04-18 | — | — | US | disclosed |
| CN-101336244-A | 9-membered heterobicyclic compounds useful as protein kinase inhibitors | ABBOTT LAB (US) | 2008-12-31 | — | — | CN | disclosed |
| WO-2008009077-A2 | 4,6-DL- AND 2,4,6-TRISUBSTITUTED QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008009076-A2 | SUBSTITUTED PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008003149-A2 | SUBSTITUTED PTERIDINES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES , INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| WO-2007066102-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-06-14 | — | — | WO | disclosed |
| EP-1169316-B9 | NOVEL LIPOIC ACID DERIVATIVES, THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SOD CONSEILS RECH APPLIC (FR) | 2003-10-29 | — | — | EP | disclosed |
| EP-1169316-B1 | NOVEL LIPOIC ACID DERIVATIVES, THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SOD CONSEILS RECH APPLIC (FR) | 2003-03-05 | — | — | EP | disclosed |
| EP-1169316-A1 | NOVEL LIPOIC ACID DERIVATIVES, THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000059899-A1 | NOVEL LIPOIC ACID DERIVATIVES, THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SOCIETE DE CONSEIL DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189440-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | TLR7, TLR8, TLR9 | PLG 4319/4885KLK1 3892/4885KLK6 3192/4885 |
| US-11987568-B2 | Allosteric inhibitor of WEE1 kinase | WEE1, WEE2, PAXBP1 | PLG 4219/4885KLK1 835/4885KLK6 1719/4885 |
| US-20230159554-A1 | COMPOUND WITH ANTICANCER ACTIVITY | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 | PLG 4080/4885KLK1 857/4885KLK6 737/4885 |
| US-11629152-B2 | Compound with anticancer activity | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, RCC2 | PLG 4080/4885KLK1 857/4885KLK6 737/4885 |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | PLG 1938/4885KLK1 2102/4885KLK6 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.